The Business Model

The Centre of Expertise on Gender Dysphoria (KZcG) at Amsterdam UMC, VUmc site, has treated the vast majority of Dutch gender patients since the 1970s.

2018 annual report: ~€13M revenue, +3.3% growth, ~70 new adult patients/month, ~40 new child patients/month, 22,000 consultations/year, ~700 surgeries/year.

Realistic estimate for 2024/2025: €20–25M gender-related revenue. Official figures are unavailable — gender care is multidisciplinary and spread across endocrinology, psychiatry, plastic surgery and urology in the annual accounts.

See also: Current status in the Netherlands, Origins — VUmc Amsterdam.

UMCG (Groningen) — second-largest integrated provider. Adults only until 2024; since 2024 also youth care, partly under pressure from the waiting lists elsewhere.

Radboud UMC (Nijmegen) — active in transgender care since 2020, treats both adults and children.

Combined gender-related revenue: €15–25M per year, not separately isolable from their annual accounts.

Until 2016 Amsterdam UMC held a practical monopoly. According to a 2022 government report, at least 14 psychological providers, 14 endocrinological and 4 surgical clinics have entered since.

Combined: €15–20M per year, excluding the cosmetic-adjacent market (mastectomy, hair removal, voice training).

Transgender care is a long-term medication market. With tens of thousands of Dutch people on hormone substitution, this is a structural, predictable pharma market. The Dutch share alone runs into tens of millions per year.

• Health insurers — Zilveren Kruis, VGZ, CZ, Menzis
• Patients — own-risk excess from age 18; under 18 falls under the Youth Act
• National government — basic insurance and (partially) the Youth Act

Total direct care costs: €40–60M/year. Including the adjacent market (pharmacy hormones, speech therapy, cosmetic procedures, mental health): approaching €80–100M/year.

Further commercialisation

The Amsterdam UMC × Gender Clinic alliance (January 2026) is likely the first of several public-private partnerships.

The Cass effect

The Cass Review (2024) landed like a bomb across Europe. England closed the Tavistock clinic and effectively stopped puberty blockers for minors. Sweden, Finland and Denmark moved earlier. The Netherlands has so far reacted defensively — see Response VUmc / Amsterdam UMC. Political pressure is rising.

Lawsuits

February 2024: four transgender lawsuits filed. A principled ruling (as with the UK Keira Bell case) could prompt insurers to revise their risk analysis.

Insurance pressure

Coverage in 2026 still sits fully in the basic insurance package. With rising healthcare costs, a revision — particularly for elective components — is not unthinkable.

New growth segments

• Non-binary care — new revenue model
• Detransition care — untapped market, internationally rising
• Fertility preservation — premium segment for young people starting hormone therapy

Dutch transgender care has grown in fifteen years from an academic niche into a commercial sector of around €40–60M direct care per year, with a much larger adjacent market. The biggest earners are the academic centres — Amsterdam UMC first — but private clinics are gaining ground fast.

The real question for 2026 is not whether the sector keeps growing, but where the money flows — and what The Hague does if the Cass doctrine breaks through here too.